Open Access

MicroRNA‑200c reverses drug resistance of human gastric cancer cells by targeting regulation of the NER‑ERCC3/4 pathway

  • Authors:
    • Min Li
    • Min Gao
    • Xiaoque Xie
    • Yiyin Zhang
    • Jie Ning
    • Pingping Liu
    • Kangsheng Gu
  • View Affiliations

  • Published online on: May 2, 2019     https://doi.org/10.3892/ol.2019.10304
  • Pages: 145-152
  • Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Gastric cancer (GC) is one of the most common types of malignant tumor. Due to the lack of effective drugs and the emergence of chemotherapy resistance, patients with GC exhibit a poor prognosis and low survival rate. MicroRNAs (miRNAs/miRs) serve an important role in drug resistance of different types of cancer. They may be suitable for use as biomarkers in the diagnosis, treatment and prognosis of tumors. The present study aimed to investigate the molecular mechanism underlying the ability of miR‑200c‑3p to reverse drug resistance in a SGC7901/DDP GC cell line, particularly its effects on the ERCC excision repair 3, TFIIH core complex helicase subunit (ERCC3) and ERCC excision repair 4, endonuclease catalytic subunit (ERCC4) proteins in the nucleotide excision repair (NER) pathway. Reverse transcription‑quantitative polymerase chain reaction demonstrated that miR‑200c‑3p expression in cisplatin‑resistant SGC7901/DDP cells was lower than in parental SGC7901 cells, whereas the protein expression levels of ERCC3 and ERCC4 in these cells were higher by western blot analysis. In SGC7901/DDP‑derived miR‑200c‑3p overexpressing cells, ERCC3 expression, ERCC4 expression and cisplatin resistance were decreased compared with in parental SGC7901/DDP cells and SGC7901/DDP‑derived vector control cells. In SGC7901‑derived miR‑200c‑3p knockdown cells, ERCC3 expression, ERCC4 expression and cisplatin resistance were increased compared with in parental SGC7901 cells and SGC7901‑derived vector control cells. In conclusion, overexpression of miR‑200c‑3p may reverse drug resistance in the SGC7901/DDP GC cell line via downregulation of ERCC3 and ERCC4, which suggested this may be part of a mechanism involving the NER pathway.
View Figures
View References

Related Articles

Journal Cover

July-2019
Volume 18 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Li M, Gao M, Xie X, Zhang Y, Ning J, Liu P and Gu K: MicroRNA‑200c reverses drug resistance of human gastric cancer cells by targeting regulation of the NER‑ERCC3/4 pathway. Oncol Lett 18: 145-152, 2019
APA
Li, M., Gao, M., Xie, X., Zhang, Y., Ning, J., Liu, P., & Gu, K. (2019). MicroRNA‑200c reverses drug resistance of human gastric cancer cells by targeting regulation of the NER‑ERCC3/4 pathway. Oncology Letters, 18, 145-152. https://doi.org/10.3892/ol.2019.10304
MLA
Li, M., Gao, M., Xie, X., Zhang, Y., Ning, J., Liu, P., Gu, K."MicroRNA‑200c reverses drug resistance of human gastric cancer cells by targeting regulation of the NER‑ERCC3/4 pathway". Oncology Letters 18.1 (2019): 145-152.
Chicago
Li, M., Gao, M., Xie, X., Zhang, Y., Ning, J., Liu, P., Gu, K."MicroRNA‑200c reverses drug resistance of human gastric cancer cells by targeting regulation of the NER‑ERCC3/4 pathway". Oncology Letters 18, no. 1 (2019): 145-152. https://doi.org/10.3892/ol.2019.10304